NAFLD, also known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common condition that the US National Institute of Diabetes and Digestive and Kidney Diseases estimates affects about 24 percent of US adults. It is strongly linked to obesity, insulin resistance, and high blood pressure, and its effects spread far beyond the liver due to its influence on whole-body metabolism.
Previous research in mice has shown that the non-psychoactive compounds cannabidiol (CBD) and cannabigerol (CBG), which are both derived from the cannabis plant, can reduce liver inflammation and slow the progression of the disease. While some research has shown that these compounds have beneficial metabolic effects, results have been conflicted and the mechanisms behind the specific effect on MASLD weren’t understood.
